Swin UNETR-based prediction of [68Ga]Ga-FAPI-46 PET/CT dose rate maps in cancer patients: quantitative comparison with [18F]FDG PET/CT

Fibroblast activation protein (FAP) is a promising theranostic target due to its high stroma expression in numerous malignancies. This study presents the first DL-based framework for predicting dose rate maps (DRMs) from [ 68 Ga]Ga-FAPI-46 PET/CT, following a quantitative and dosimetric comparison with [ 18 F]FDG PET/CT. The approach supports personalized pre-therapeutic planning in radiopharmaceutical therapies (RPTs). PET/CT scans with [ 68 Ga]Ga-FAPI-46 and [ 18 F]FDG from 22 cancer patients were retrospectively analyzed. DRMs were generated using the dose voxel kernel (DVK) method using the GATE toolkit. Absorbed doses (ADs) obtained from DVK-based DRMs for tumors and organs at risk (OARs) were compared with those derived from full Monte Carlo (MC), and local energy deposition (LED), based DRMs, and organ-level estimates calculated using OLINDA/EXM v1.1. Tracer uptake of [ 68 Ga]Ga-FAPI-46 and [ 18 F]FDG was compared using SUV max , SUV mean , and tumor-to-background ratio (TBR). A shifted windows UNEt TRansformers (Swin UNETR) model was trained to predict DRMs and benchmarked against ResNet-32 using R², RMSE, and gamma index. [ 68 Ga]Ga-FAPI-46 PET/CT demonstrated higher TBRs and lower OARs uptake and ADs compared to [ 18 F]FDG, indicating its promise in enhancing lesion detectability. The Swin UNETR model achieved an RMSE of 0.0598 Gy 2 /s, R 2 of 0.960, and a gamma pass rate of 98.71%, outperforming ResNet-32. Compared to [ 18 F]FDG, [ 68 Ga]Ga-FAPI-46 PET offers higher image contrast, better lesion detectability, and improved dosimetric profiles, supporting personalized RPT planning. While Swin UNETR enables fast and accurate DRM prediction from [ 68 Ga]Ga-FAPI-46, broader validation in larger, multicenter cohorts is needed to ensure reproducibility and clinical impact.